Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2 Positive Breast Cancer: Real-World Data from a National Institute of Oncology in Poland.

Agnieszka Irena Jagiełło-Gruszfeld
* ,
Magdalena Rosinska
,
Malgorzata Meluch
,
Katarzyna Pogoda
ORCID logo ,
Anna Niwińska
,
Renata Sienkiewicz
,
Aleksander Grous
,
Pawel Winter
ORCID logo ,
Zbigniew I. Nowecki
Version 1 : Received: 8 January 2022 / Approved: 12 January 2022 / Online: 12 January 2022 (13:31:16 CET)

A peer-reviewed article of this Preprint also exists.

Jagiełło-Gruszfeld, A.I.; Rosinska, M.; Meluch, M.; Pogoda, K.; Niwinska, A.; Sienkiewicz, R.; Grous, A.; Winter, P.; Nowecki, Z.I. Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers 2022, 14, 1218. Jagiełło-Gruszfeld, A.I.; Rosinska, M.; Meluch, M.; Pogoda, K.; Niwinska, A.; Sienkiewicz, R.; Grous, A.; Winter, P.; Nowecki, Z.I. Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers 2022, 14, 1218.

Abstract

Neoadjuvant systemic therapy has now become the the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/- pertuzumab targeted therapy can improve rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is considered a good prognostic factor, in particular in patients with more aggressive breast cancer subtypes such as TNBC or HER2 positive cancers. Furthermore, most studies demonstrate that chemotherapy in combination with trastuzumab and pertuzumab is well tolerated. The retrospective analysis presented here concentrates on neoadjuvant therapy with the TCbH-P regimen, with a particular emphasis on patients over 60 years of age. We analysed the factors affecting the achievement of pCR and presented adverse effects of the applied therapies, which opened a discussion about optimizing the therapy of older patients with HER-2 positive breast cancer.

Keywords

breast cancer,; neoadjuvant chemotherapy; elederly; HER2- positive; pathological complete response; safety

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.